الفهرس 
LIST OF CONTENTS
HISTOPATHOLOGY AND IMMUNOPHENOTYPINGOnly 14 pages are availabe for public view
 |  | from | 118 |  |  |
| | | from | 118 | | |
Abstract
This prospective study evaluated the treatment results of children diagnosed as NHL at Pediatric Oncology Department SECI Assiut University from August 2001 to August 2005 with minimum follow up one year after termination of treatment. The study included 40 patients, their age ranged between 2.5-14 years, their mean age was 6 and median was 6.8 years. The male to female ratio was 2.3:1.
In our study 67% of patients had systemic symptoms, 72.3% of patients had extranodal disease and 27.5% had nodal disease. 50% presented with abdominal mass, 22.5% had thoracic involvement, peripheral node enlargement was found in 12.5%, head and neck presentation in 10%, whereas only 5% had paraspinal mass.
Malnutrition was reported in 18 (45%) of patients and profound anemia (hemoglobin less than 7 g/100ml) in 16 (40%) of patients.
Fourteen patients (35%) had LDH level below 500U/L while 26 (65%) had their LDH level more than 500U/L. The median LDH level was 880 U/L (range 120- 11000)
In our study we depended on two markers for classification: CD20 for B-cell Lymphoma and CD3 for T-cell Lymphoma and this were available for 28 patients. The majority of patients 20 (78%) were B-cell and 8 (22%) were positive for T-cell Lymphoma. Histopathologic classification showed 12 patients to be diagnosed as LBL (group I), 19 patients as BL (group II) and 9 patients as LCL (group III). The majority of our patients (57%) were stage III and (43%) were stage IV according to St.Jude classification system. In our study, patients were treated according to histopathology: group I by modified BFM- NHL protocol, group II by modified LMB 89 protocol and group III by modified BFM-NHL protocol. Modification in doses was done to comply with available supportive care.